Emmanuelle SAMALIN
Institut du Cancer de Montepllier · Institut Régional du Cancer de Montpellier (ICM) · Institut régional du cancer de Montpellier
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Emmanuelle SAMALIN as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:55 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06245356 · Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal CancerUNICANCER · recruiting · Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency · principal investigator
- N/ANCT04186117 · Development of Clinical and Biological Database in Colorectal CancerInstitut du Cancer de Montpellier - Val d'Aurelle · completed · Metastatic Colon Cancer · study chair
- N/ANCT03914170 · Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal CancerInstitut du Cancer de Montpellier - Val d'Aurelle · completed · Colorectal Cancer · principal investigator
- Ph3NCT03829462 · Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer PatientsInstitut du Cancer de Montpellier - Val d'Aurelle · active not recruiting · Metastatic Colorectal Cancer (mCRC) · study chair
- Ph1/Ph2NCT03722108 · Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal AdenocarcinomasUNICANCER · terminated · Adenocarcinoma of the Stomach, Adenocarcinoma of the Gastroesophageal Junction · principal investigator
- Ph2NCT01919879 · Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal CancerUNICANCER · completed · Metastatic Colorectal Cancer · principal investigator
- Ph2NCT01715441 · Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated TumorsInstitut du Cancer de Montpellier - Val d'Aurelle · completed · Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors · principal investigator
- Ph2NCT01532804 · 2nd-line Treatment of Metastatic Colorectal CancerInstitut du Cancer de Montpellier - Val d'Aurelle · terminated · Metastatic Colorectal Cancer · principal investigator
- Ph2NCT01443065 · MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal AdenocarcinomaUNICANCER · completed · Malignant Neoplasm of Esophagus, Malignant Neoplasm of Stomach · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:55 UTC. The ranking covers the 200 most relevant of 26 PubMed records, and a shared surname and initials can bring in a namesake. All 26 on PubMed
- 106 citationsRCR 3.0
- Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance.Gastric Cancer · 2020100 citationsRCR 3.9
- 72 citationsRCR 4.1
- Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.Oncologist · 201169 citationsRCR 1.7
- 55 citationsRCR 1.5
- 48 citationsRCR 1.3
- 41 citationsRCR 1.4
- 37 citationsRCR 1.3
- Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).Int J Cancer · 202129 citationsRCR 1.4
- Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.Dig Liver Dis · 202229 citationsRCR 1.7